RxDoctor Payments DataLook up a doctor →

Stephen Bernstein, MD

Rheumatology · New York, NYNPI 1215017736

Payments from drug & device makers

$208,111in general payments, 2019–2025

Across 1,299 payments — averaging $160.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$107K
  • Mallinckrodt Hospital Products Inc.$46K
  • Mallinckrodt Enterprises LLC$31K
  • Amgen$4K
  • Eli Lilly$2K
  • AstraZeneca$2K
  • plus $15K from 39 others

What the payments were for

  • Consulting fees$4,9652%
  • Speaking & faculty fees$161,15577%
  • Travel & lodging$8,1534%
  • Food & beverage$33,53816%
  • Education$2600%
  • Gifts$410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$208,111 in reported general payments places this provider in the 85th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$300,082
Medicare patients
123
Services billed
16,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab23$203,235
RinvoqUpadacitinib23$153,834
Xeljanz XrTofacitinib Citrate23$129,609
SaphneloAnifrolumab-Fnia12$60,602
OzempicSemaglutide37$43,957
ActemraTocilizumab11$38,122
Repatha SureclickEvolocumab48$34,045
RybelsusSemaglutide14$28,333
MounjaroTirzepatide13$15,611
FarxigaDapagliflozin Propanediol15$14,134
EliquisApixaban17$13,240
JardianceEmpagliflozin11$8,823
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$7,968
Colchicine44$5,018
Methylprednisolone110$3,399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Synthroid$107,196$157,14049 claims
AstraZenecaSaphnelo, Farxiga$2,098$74,73627 claims
Novo NordiskOzempic, Rybelsus$1,941$72,29051 claims
Lilly USA, LLCMounjaro$1,259$15,61113 claims
PfizerEliquis$1,721$13,24017 claims
Boehringer IngelheimJardiance$223$8,82311 claims
GSKTrelegy Ellipta$1,247$7,96813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 541 rheumatology providers in New York.

Other rheumatology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →